+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019

  • ID: 4901391
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1370 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • Cellestia Biotech AG
  • Faron Pharmaceuticals Oy
  • J-Pharma Co Ltd
  • Oasmia Pharmaceutical AB
  • Sanofi
  • MORE
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 78, 55, 1, 26, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages comprises 6, 4, 2, 1 and 4 molecules, respectively.

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • Cellestia Biotech AG
  • Faron Pharmaceuticals Oy
  • J-Pharma Co Ltd
  • Oasmia Pharmaceutical AB
  • Sanofi
  • MORE
Introduction
Bile Duct Cancer (Cholangiocarcinoma) - Overview
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbbVie Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbGenomics International Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ability Pharmaceuticals SL, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ABM Therapeutics Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Alphamab Oncology, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Andes Biotechnologies, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Apollomics Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ascelia Pharma AB, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BioMed Valley Discoveries Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Co, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celldex Therapeutics Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellestia Biotech AG, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celltrion Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celon Pharma SA, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Clovis Oncology Inc, H2 2019
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Coherent Biopharma, H2 2019

List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • AbbVie Inc
  • AbGenomics International Inc
  • Ability Pharmaceuticals SL
  • ABM Therapeutics Inc
  • Advenchen Laboratories LLC
  • Agios Pharmaceuticals Inc
  • Alphamab Oncology
  • Andes Biotechnologies
  • Apollomics Inc
  • ArQule Inc
  • Ascelia Pharma AB
  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Betta Pharmaceuticals Co Ltd
  • BioMed Valley Discoveries Inc
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Celltrion Inc
  • Celon Pharma SA
  • Clovis Oncology Inc
  • Coherent Biopharma
  • Convalife
  • Corcept Therapeutics Inc
  • CSPC Pharmaceutical Group Ltd
  • CStone Pharmaceuticals Co Ltd
  • Curegenix Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Delcath Systems Inc
  • Delta-Fly Pharma Inc
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Forma Therapeutics Inc
  • Fujifilm Holdings Corp
  • Genentech Inc
  • Genoscience Pharma
  • GlaxoSmithKline Plc
  • GO Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • H3 Biomedicine Inc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hutchison MediPharma Ltd
  • ImCare Biotech LLC
  • Immunitor Inc
  • Incyte Corp
  • Inmune Bio Inc
  • InnoCare Pharma Ltd
  • Innopharmax Inc
  • Intensity Therapeutics Inc
  • Ipsen SA
  • J-Pharma Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Kangen Pharmaceuticals Co Ltd
  • Karus Therapeutics Ltd
  • Komipharm International Co Ltd
  • Leap Therapeutics Inc
  • Lexicon Pharmaceuticals Inc
  • Lokon Pharma AB
  • Luzitin SA
  • Marino Biotechnology Co Ltd
  • Mebiopharm Co Ltd
  • MediciNova Inc
  • Medivir AB
  • Merck & Co Inc
  • Merck KGaA
  • Mina Therapeutics Ltd
  • Molecular Templates Inc
  • Mundipharma EDO GmbH
  • Nanjing Transthera Biosciences Co Ltd
  • NanoCarrier Co Ltd
  • Newish Technology Beijing Co Ltd
  • Nkarta Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • NuCana Plc
  • Oasmia Pharmaceutical AB
  • Oncocross Co Ltd
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Orgenesis Inc
  • PCI Biotech Holding ASA
  • Pfizer Inc
  • Pharma Mar SA
  • Provecs Medical GmbH
  • Puma Biotechnology Inc
  • Puretech Health Plc
  • QED Therapeutics Inc
  • Rafael Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Redx Pharma Plc
  • RemeGen Ltd
  • Rgenix Inc
  • Samyang Holdings Corp
  • Sanofi
  • Seald AS
  • Senhwa Biosciences Inc
  • Sensei Biotherapeutics Inc
  • Shanghai Haihe Biopharma Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sillajen Biotherapeutics
  • Sinocelltech Ltd
  • Sirnaomics Inc
  • SMT bio Co Ltd
  • Sorrento Therapeutics Inc
  • Starpharma Holdings Ltd
  • Sun Pharma Advanced Research Company Ltd
  • SupremeCure Pharma Inc
  • SynCore Biotechnology Co Ltd
  • Syndax Pharmaceuticals Inc
  • SyntheX Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • TCR2 Therapeutics Inc
  • tella Inc
  • Tempest Therapeutics Inc
  • Therillia Development Co Inc
  • Toray Industries Inc
  • TOT Biopharm Co Ltd
  • VasGene Therapeutics Inc
  • Xencor Inc
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
Adroll
adroll